Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen

Johan RosellRegional Cancer Center South East Sweden, Linköping, Sweden; ;Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden; Correspondence[email protected]

Bo NordenskjöldOncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden;

Nils-Olof BengtssonDepartment of Oncology, Umeå University Hospital, Umeå, Sweden;

Tommy FornanderDepartment of Oncology, Karolinska University Hospital, Stockholm, Sweden;

Thomas HatschekDepartment of Oncology, Karolinska University Hospital, Stockholm, Sweden;

Henrik LindmanDepartment of Oncology, Uppsala University Hospital, Uppsala, Sweden;

Per-Olof MalmströmSkånes Department of Oncology, Skåne University Hospital, Lund, Sweden;

Arne WallgrenDepartment of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden;

Olle StålOncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden;

John CarstensenDepartment of Medical and Health Sciences, Linköping University, Linköping, Sweden

show all

References

Mellemkjaer L, Steding-Jessen M, Fredriksen K, et al. Risk of contralateral breast cancer after tamoxifen use among Danish women. Ann Epidemiol. 2014;24:843–848.
PubMed Web of Science ®Google Scholar
Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97:375–384.
PubMedGoogle Scholar
Nordenskjöld B, Rosell J, Rutqvist LE, et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst. 2005;97:1609–1610.
PubMed Web of Science ®Google Scholar
Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67–75.
PubMed Web of Science ®Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784.
PubMed Web of Science ®Google Scholar
Bouchardy C, Benhamou S, Schaffar R, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer. 2011;117:1288–1295.
PubMed Web of Science ®Google Scholar
Rutqvist LE, Johansson H. Stockholm Breast Cancer Group. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 2007;46:133–145.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date